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 Antibiotics were excessively used in hospitalised COVID-19 patients. 
 COVID-19 caused major disruptions to AMR surveillance and research. 
 Global data on the use of antibiotics during the COVID-19 pandemic is needed. 
 Antimicrobial resistance needs continued public and political engagement. 
 
 
The COVID-19 pandemic is predicted to impact the transmission of bacterial infections and 
the emergence of antibiotic resistance (AMR). The likely positive influence on antibiotic 
resistance that social distancing, increased awareness and the use of interventions to prevent 
the transmission of COVID-19 has had could also be counteracted by the reported excessive 
use of broad spectrum antibiotics to treat patients infected with SARS-CoV-2. Antimicrobial 









the COVID-19 and future pandemics, in order to safeguard against an uncontrolled rise in 
AMR.  
Antibiotic use in the COVID-19 pandemic 
The priority during the COVID-19 pandemic has been treating patients and avoiding 
acquisition of SARS-CoV-2 by healthcare personnel whilst maintaining functionality of the 
healthcare systems. Within healthcare, there has been a need to redirect personnel, resources 
and attention to COVID-19 diagnosis and management. AMR surveillance and screening 
programmes to detect colonisation by resistant organisms have been compromised due to 
shortage of personnel and the need to redirect molecular diagnostic platforms, reagents, 
tracking and tracing from AMR surveillance to COVID-19 diagnostics. 
It has been reported that only 7-8% of hospitalised COVID-19 patients were diagnosed with 
a bacterial or fungal infection [1, 2, 3], while antibiotic use in COVID-19 patients has been 
considerably high: 71.9% (95% CI: 56.1-87.7) [3]. Further studies using molecular 
techniques on samples from ventilated and non-ventilated COVID-19 patients are needed. 
Whether new or evolving AMR in COVID-19 patients will emerge in areas with low 
previous rates should be examined in retrospective and prospective clinical and 
microbiology studies.  
Simultaneously managing the acute COVID-19 pandemic and escalating AMR 
COVID-19 has illustrated the vulnerability of our healthcare systems. This is even more 
noticeable in Low and Middle Income Countries (LMICs) and in resource-constrained 
settings less prepared to deal with pandemics or other emergencies [4-6]. Local, national and 
international scale resistance data is needed to help researchers better understand potential 
disruptions in stewardship and surveillance efforts, and highlight the early emergence of 
resistance due to antibiotic use linked to COVID-19 and secondary infections. 
Co-managing multiple infectious disease threats simultaneously is a further challenge for 









and AMR are often unreliable and infection prevention and control policies, practice and 
personnel are sub-optimal and, or, unsustainable [7]. Regulated antibiotic use is difficult to 
enforce where there is poor access to antibiotics overall, while socio-behavioural 
interventions such as physical distancing and hand hygiene can be limited, especially in 
areas with high population densities with limited access to clean water and sanitation 
services Thus, an exit strategy from COVID-19 for many LMICs may not be 
pharmacologically based in the short term and more community-based strategies are 
currently being explored [8]. 
Impact of the COVID-19 pandemic on AMR research  
A critical lesson from the COVID-19 pandemic is the importance of embedding research in 
the response. Supporting good quality implementation research could help understand not 
only what has worked, but also how and why an intervention was successful. While research 
on COVID-19 due to the pandemic has progressed, research in other fields including AMR 
has been deprioritised, delayed, or even halted. Delays limit scientists to meet deadlines and 
targets within projects, and restrict sharing of information and networking activities. 
Funding agencies across the globe have given research grant extensions; however, the long-
term impact on AMR research is yet to be understood and factors such as the effect on early 
career researchers may take years to manifest. As solidarity pledges emerge to address 
COVID-19, so too must efforts to openly share research and data ’on AMR, including 
surveillance data from the pharmaceutical industry, as incentivised by the Access to 
Medicine Foundation’s AMR Benchmark. In order to ensure that AMR research continues 
to be adequately supported it is important to prioritise funds for AMR research at both 
national and international scales.  
 
The COVID-19 pandemic has led to an unprecedented awareness of the importance of 









community is in an ideal position to raise the awareness of the topic of AMR and build 
on community engagement in the importance of sanitary infrastructures [9], 
handwashing, disinfection, social distancing when ill, and avoiding unnecessary use of 
antibiotics. Harnessing the public understanding of the relevance of infectious diseases 
towards the long-term pandemic of AMR could have major implications for promoting 
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